New study checks safety of RSV prevention drug in vulnerable infants
NCT ID NCT06851806
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests the safety of palivizumab, a drug given as monthly injections, in infants under 24 months who are at high risk for severe RSV disease. About 138 children born prematurely or with certain lung or heart conditions will receive up to 5 doses. Researchers will monitor for side effects and serious adverse events.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
palivizumab
What this could lead to
If successful, this study could confirm that palivizumab is safe for preventing severe RSV in high-risk infants, supporting its continued use.
What could go wrong
This is a small, open-label safety study with no placebo group, so it cannot prove effectiveness. Side effects may still occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGHyderabad, 500084, India
-
Research Site
NOT_YET_RECRUITINGPune, 411006, India